Timo Soeterik

48 CHAPTER 3 TABLE 1. Baseline characteristics of the AS patient population by hospital Hospital 1 Hospital 2 Hospital 3 Hospital 4 Hospital 5 Hospital 6 p Patients ( N ) 248 144 166 178 78 186 Age, SD (years) 67.9 ± 6.4 67.3 ± 6.5 68.1 ± 6.6 67.4 ± 5.6 67.6 ± 5.7 65.3 ± 6.8 <0.001 PSA (ng/ml) 8.2 ± 5.4 7.4 ± 3.4 7.0 ± 3.3 9.2 ± 4.8 8.2 ± 4.1 8.6 ± 4.9 <0.001 PSAD (ng/ml/ml) a 0.17 ± 0.14 0.18 ± 0.11 0.14 ± 0.07 0.21 ± 0.12 0.19 ± 0.11 0.18 ± 0.12 <0.001 cT stage, N (%) b T1c T2a T2b T2c T2 T3/T4 200 (81) 11 (4) 2 (1) 4 (2) 24 (10) 7 (3) 110 (76) 10 (7) 1 (1) 3 (2) 19 (12) 1 (1) 104 (63) 25 (15) 4 (2) 0 (0) 31 (19) 2 (1) 144 (81) 8 (5) 7 (4) 4 (2) 15 (8) 0 (0) 74 (95) 1 (1) 0 (0) 0 (0) 3 (3) 0 (0) 156 (84) 9 (5) 0 (0) 4 (2) 16 (9) 1 (1) Total biopsy cores 9.4 ± 2.1 9.5 ± 1.7 8.9 ± 2.2 8.7 ± 2.4 9.9 ± 0.7 8.1 ± 1.2 <0.001 No. positive cores 1.8 ± 1.1 1.6 ± 1.0 1.6 ± 0.9 1.8 ± 1.2 1.6 ± 1.1 1.4 ± 0.8 <0.001 Gleason score N (%) 4 5 3 + 3 3 + 4 4 + 3 0 (0) 0 (0) 230 (93) 15 (6) 3 (1) 3 (2) 5 (4) 126 (88) 10 (6) 0 (0) 0 (0) 0 (0) 165 (99) 1 (1) 0 (0) 0 (0) 0 (0) 171 (96) 6 (3) 1 (1) 0 (0) 2 (3) 74 (95) 2 (3) 0 (0) 2 (1) 3 (2) 169 (91) 12 (7) 0 (0) Risk Group N (%) c PRIAS-eligible PRIAS-ineligible 123 (50) 125 (50) 85 (59) 59 (41) 104 (63) 62 (37) 60 (34) 118 (66) 36 (46) 42 (54) 102 (55) 84 (45) a PSAD; PSA density = PSA / prostate volume measured by TRUS or MRI. b Clinical T stage based on digital rectal examination and transrectal ultrasonography. c Risk classification based on PRIAS: PRIAS-eligible: PSA≤10 ng/ml, PSAD <0.2, Gleason ≤6, <3 positive biopsy cores and clinical stage ≤T2. PRIAS-ineligible: not complying to one or more of the abovementioned PRIAS inclusion criteria.